Publications by authors named "Peter L Greenberg"

67Publications

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Nat Med 2020 Aug 3. Epub 2020 Aug 3.

Computational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41591-020-1008-zDOI Listing
August 2020

Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.

Cytometry B Clin Cytom 2020 03 9;98(2):131-145. Epub 2020 Jan 9.

Baxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21860DOI Listing
March 2020

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

N Engl J Med 2020 01;382(2):140-151

From Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris (P.F., L.A.), Service des Maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire (CHU) de Lille, Lille (B.Q.), the Department of Internal Medicine, CHU Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse (O.B.-R.), and Université Cote d'Azur, Département d'Hématologie Clinique, CHU Nice, Nice (T.C.) - all in France; Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig (U.P.), Klinik für Hämatologie, Onkologie, and Klinische Immunologie, Universitätsklinik Düsseldorf, Düsseldorf (U.G.), and Klinik und Poliklinik für Innere Medizin III, Technische Universität München, Munich (K.S.G.) - all in Germany; the Department of Haemato-Oncology, King's College London, London (G.J.M.), Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford (P.V.), and the Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds (D.B.) - all in the United Kingdom; the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.G.-M.); Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (R.B.); MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence (V.S.), the Department of Oncology and Hematology, S. Orsola-Malpighi University Hospital, Bologna (C.F.), the University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia (M.C.), the Hematology Unit, Santi Antonio e Biagio e Cesare Arrigo Hospital, Alessandria (F.S., V.G.), and Dipartimento Biomedicina e Prevenzione, University of Rome Tor Vergata, Rome (M.-T.V.) - all in Italy; the Hematology Department, University Hospital of Salamanca, Institute of Biomedical Research of Salamanca, Salamanca (M.D.-C.), Unidad de Hematología, Hospital Universitario Virgen del Rocío, Seville (J.F.F.), and the Department of Hematology, Hospital Universitario Cruces, Vizcaya (B.A.) - all in Spain; the Department of Hematology Science, School of Medicine, Ankara University, Ankara, Turkey (O.I.); the Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland (M.A.S.); the Department of Hematology, Algemeen Ziekenhuis Sint-Jan, Bruges (D.S.), and Universitair Ziekenhuis Gent, Ghent (D.M.) - both in Belgium; the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (A.E.D.); the Division of Hematology-Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center (J.G.J.), and Albert Einstein College of Medicine (A.V.) - both in New York; the Department of Hematology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands (E.V.); Stanford University Cancer Center, Stanford, CA (P.L.G.); the Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm (E.H.-L.); the Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT (A.M.Z.); Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville (M.R.S.); Celgene, Summit, NJ (A.L., J.Z., A.R., D.R.D.); Celgene International, Boudry, Switzerland (A.B.); Acceleron Pharma, Cambridge, MA (P.G.L., M.L.S.); and Moffitt Cancer Center, Tampa, FL (R.S.K., A.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908892DOI Listing
January 2020

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Blood Adv 2018 10;2(20):2787-2797

Stanford University Cancer Center, Stanford, CA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018015834DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6199665PMC
October 2018

Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells.

Leuk Lymphoma 2018 12 4;59(12):2952-2962. Epub 2018 Apr 4.

b Hematology Division , Stanford University School of Medicine, Stanford Cancer Institute , Stanford , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1452210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214785PMC
December 2018

The classical nature of distinctive CMML monocytes.

Blood 2017 03;129(13):1745-1746

STANFORD CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-02-767590DOI Listing
March 2017

Immune checkpoint pathways: perspectives on myeloid malignancies.

Leuk Lymphoma 2016 May 25;57(5):995-1001. Epub 2016 Feb 25.

a Department of Medicine, Division of Hematology , Stanford Cancer Institute , Stanford , CA , USA ;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1107554DOI Listing
May 2016

Myelodysplastic syndromes, version 2.2015.

J Natl Compr Canc Netw 2015 Mar;13(3):261-72

From Stanford Cancer Institute; Dana-Farber/Brigham and Women's Cancer Center; UC San Diego Moores Cancer Center; University of Rochester Medical Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Duke Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massachusetts General Hospital Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Roswell Park Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; University of Colorado Cancer Center; Huntsman Cancer Institute at the University of Utah; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696005PMC
http://dx.doi.org/10.6004/jnccn.2015.0038DOI Listing
March 2015

MDS prognostic scoring systems – past, present, and future.

Best Pract Res Clin Haematol 2015 Mar 11;28(1):3-13. Epub 2014 Nov 11.

Department of Internal Medicine, Division of Hematology, Stanford University School of Medicine, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2014.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324398PMC
March 2015

Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.

Am J Clin Pathol 2014 Dec;142(6):795-802

From the Department of Pathology, Stanford University School of Medicine, Stanford, CA, and

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1309/AJCP71OPHKOTLSUGDOI Listing
December 2014

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

J Clin Oncol 2014 Apr 24;32(12):1242-8. Epub 2014 Mar 24.

Thomas Prebet, James Herman, Lisa Malick, and Steven D. Gore, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Zhuoxin Sun, Dana-Farber Cancer Institute, Boston, MA; Maria E. Figueroa and Ari Melnick, Weill Cornell Medical College; Janice Gabrilove, Mount Sinai School of Medicine; Martin S. Tallman, Leukemia Service, Memorial Sloane-Kettering Cancer Center, New York; Elisabeth Paietta, North Division, Montefiore Medical Center, Bronx, NY; Rhett Ketterling and Mark Litzow, Mayo Clinic, Rochester, MN; Peter L. Greenberg, Stanford University Cancer Center, Stanford, CA; Mark Juckett, University of Wisconsin, Madison, WI; Mitchell R. Smith, Fox Chase Cancer Center, Philadelphia, PA; Magdalena Czader, Indiana University Cancer Center, Indianapolis, IN; and Harry P. Erba, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.3102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986386PMC
April 2014

Update on Myelodysplastic Syndromes Classification and Prognosis.

Surg Pathol Clin 2013 Dec 21;6(4):693-728. Epub 2013 Oct 21.

Hematology Division, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.path.2013.08.005DOI Listing
December 2013

Specific plasma autoantibody reactivity in myelodysplastic syndromes.

Sci Rep 2013 Nov 22;3:3311. Epub 2013 Nov 22.

1] Department of Genetics, Stanford University School of Medicine, Stanford, California, USA [2].

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep03311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3837310PMC
November 2013

The multifaceted nature of myelodysplastic syndromes: clinical, molecular, and biological prognostic features.

J Natl Compr Canc Netw 2013 Jul;11(7):877-84; quiz 885

Hematology Division, Stanford University Cancer Center, Stanford, California 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2013.0105DOI Listing
July 2013

Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.

Proc Natl Acad Sci U S A 2013 Feb 6;110(8):3011-6. Epub 2013 Feb 6.

Institute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Cancer Stem Cell Research and Medicine, and Department of Pathology, Stanford University, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://www.pnas.org/cgi/doi/10.1073/pnas.1222861110
Publisher Site
http://dx.doi.org/10.1073/pnas.1222861110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581956PMC
February 2013

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.

Leuk Lymphoma 2013 Feb 15;54(2):321-8. Epub 2012 Nov 15.

Hematology Division, Stanford University Cancer Center, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2012.713477DOI Listing
February 2013

Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow.

Lab Invest 2012 Sep 18;92(9):1330-41. Epub 2012 Jun 18.

Research Unit, Instituto Mexicano del Seguro Social, Mexico City, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/labinvest.2012.93DOI Listing
September 2012

Myelodysplastic syndromes: dissecting the heterogeneity.

J Clin Oncol 2011 May 25;29(15):1937-8. Epub 2011 Apr 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.35.2211DOI Listing
May 2011

Current therapeutic approaches for patients with myelodysplastic syndromes.

Br J Haematol 2010 Jul 5;150(2):131-43. Epub 2010 May 5.

Hematology Division, Stanford University Cancer Center, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2010.08226.xDOI Listing
July 2010

Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.

Blood 2009 Nov 2;114(23):4847-58. Epub 2009 Oct 2.

Hematology Division,Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2009-08-236422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786292PMC
November 2009

The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.

J Natl Compr Canc Netw 2008 Oct;6(9):942-53

Stanford University Cancer Center, Stanford, California 94305-5821, USA.

View Article

Download full-text PDF

Source
http://www.jnccn.org/content/6/9/942.full.pdf
Web Search
October 2008

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.

Am J Hematol 2008 Oct;83(10):765-70

Division of Hematology, Stanford University Cancer Center, Stanford, California 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.21249DOI Listing
October 2008

Myelodysplastic syndromes: iron overload consequences and current chelating therapies.

J Natl Compr Canc Netw 2006 Jan;4(1):91-6

Hematology Division, Stanford University Cancer Center, 875 Blake Wilbur Drive, Room 2335, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
January 2006

Management of patients with higher risk myelodysplastic syndromes.

Crit Rev Oncol Hematol 2005 Nov 23;56(2):179-92. Epub 2005 Jun 23.

Division of Hematology, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305-5821, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2005.04.006DOI Listing
November 2005

Novel biospecific agents for the treatment of myelodysplastic syndromes.

J Natl Compr Canc Netw 2003 Oct;1(4):473-80

Division of Hematology, Stanford University Medical Center, Stanford, California 94305-5750, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2003.0040DOI Listing
October 2003

Myelodysplastic syndromes.

Hematology Am Soc Hematol Educ Program 2002 :136-61

Hematology Division, Stanford University Medical Center, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2002.1.136DOI Listing
August 2003